Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: Trastuzumab|DRUG: Paclitaxel|DRUG: FEC75|DRUG: Lapatinib
Sponsor: GlaxoSmithKline